LOG IN
SIGN UP
MARKET
ALPN
ALPN
Alpine Immune Sc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
9.43
+0.42
+4.66%
After Hours: 9.43 0 0.00% 16:00 05/27 EDT
OPEN
9.00
PREV CLOSE
9.01
HIGH
9.89
LOW
8.91
VOLUME
98.67K
TURNOVER
0
52 WEEK HIGH
14.40
52 WEEK LOW
6.00
MARKET CAP
286.00M
P/E (TTM)
-5.3226
1D
5D
1M
3M
1Y
5Y
BRIEF-Alpine Immune Sciences Announces Presentations At The 2022 Eular And ASCO Annual Meetings
reuters.com · 1d ago
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
SEATTLE, May 26, 2022--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the acceptance of abstracts ...
Business Wire · 1d ago
FDA lifts partial clinical hold on Alpine Immune's davoceticept for malignancies
Alpine Immune Sciences (NASDAQ:ALPN) said on Tuesday the U.S. Food and drug Administration had removed the partial clinical hold placed on trial evaluating its drug candidate davoceticept in combination with Merck's
Seekingalpha · 4d ago
FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer
Benzinga · 4d ago
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold On NEON-2 Clinical Trial Of Davoceticept (ALPN-202) In Combination With Pembrolizumab
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that the U.S.
Benzinga · 4d ago
BRIEF-Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold On Clinical Trial Of Davoceticept In Combination With Pembrolizumab
reuters.com · 4d ago
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
SEATTLE, May 24, 2022--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that the U.S. Food and Drug ...
Business Wire · 4d ago
Alpine Immune Sciences Says US FDA Lifts Partial Hold on Clinical Trial of Davoceticept Combined With Pembrolizumab
MT Newswires · 4d ago
No Data
Learn about the latest financial forecast of ALPN. Analyze the recent business situations of Alpine Immune Sc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 4 analysts
Strong Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALPN stock price target is 20.00 with a high estimate of 22.00 and a low estimate of 17.00.
Current 9.43
EPS
Actual
Estimate
-0.44-0.33-0.21-0.10
Institutional Holdings
Institutions: 65
Institutional Holdings: 26.11M
% Owned: 86.09%
Shares Outstanding: 30.33M
TypeInstitutionsShares
Increased
16
357.14K
New
9
9.41M
Decreased
17
416.02K
Sold Out
7
3.19M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/Chief Compliance Officer/Executive Director
Mitchell Gold
President
Stanford Peng
Chief Financial Officer/Senior Vice President/Secretary
Paul Rickey
Director
Jay Venkatesan
Independent Director
Robert Conway
Independent Director
Xiangmin Cui
Independent Director
Natasha Hernday
Independent Director
Christopher Peetz
Independent Director
Peter Thompson
Independent Director
James Topper
No Data
No Data
About ALPN
Alpine Immune Sciences, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The Company's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. Its product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Webull offers kinds of Alpine Immune Sciences Inc stock information, including NASDAQ:ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.